SilcsBio Co-Founder Alex MacKerell, PhD Receives ACS Award for Computers in Chemical and Pharmaceutical Research

Dr. MacKerell to be honored at the ACS Spring 2022 National Meeting, March 20-24, in San Diego March 10, 2022, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, announced today its Co-Founder and Chief Scientific Officer, Alexander D. MacKerell Jr., PhD, has been awarded the […]

Continue Reading

Technical Sales for Drug Design Portfolio

Immediate Job Opening – 1/20/2022 Technical Sales Within Early Charm’s Drug Design Portfolio   SilcsBio’s parent company, Early Charm, has a job opening to work with SilcsBio and other companies in its Drug Design Portfolio.   What we do: Early Charm creates, owns, and operates businesses that convert science into revenue. We are the management […]

Continue Reading

SilcsBio Spinout Raises $1.5 Million Investment

FOR IMMEDIATE RELEASE:   SilcsBio Spinout Raises $1.5 Million to Advance Drug Development New investment from Bluedot Bio into Rasio follows initial funding from the National Foundation for Cancer Research   December 2, 2021, Baltimore, MD – Rasio Therapeutics, a joint venture formed by SilcsBio and the National Foundation for Cancer Research (NFCR) to develop […]

Continue Reading